Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug shows promise for rare swelling disease

NCT ID NCT04602598

First seen Apr 01, 2026 · Last updated May 25, 2026 · Updated 9 times

Summary

This study tested a drug called zanubrutinib in 10 adults with IgG4-related disease, a condition that causes swelling in glands and other organs. The goal was to see if the drug could safely reduce gland swelling and inflammation. Participants took the drug for 24 weeks, and researchers measured changes using PET-MRI scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGG4 RELATED DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Stanford University

    Palo Alto, California, 94304, United States

Conditions

Explore the condition pages connected to this study.